From ecDNA structure to tumor immune escape and therapeutic resistance: evidence, uncertainty, and clinical priorities
- 1niversity of South Asia, Bishkek, Kyrgyzstan
Abstract
Extrachromosomal DNA (ecDNA) is a structurally distinct form of focal amplification that can increase oncogene dosage, reorganize enhancer–promoter interactions, and accelerate tumor evolution through unequal segregation. This review presents a single, evidence-based sequence: the structure of ecDNA confers an evolutionary capacity; selection then acts upon the genes and regulatory elements that are carried by ecDNA; the clones that have been selected may subsequently develop treatment-adaptive or immune-associated traits; and clinical application can only proceed once it has been demonstrated that ecDNA provides information that goes beyond what is seen in conventional amplification. The strongest evidence comes from unequal segregation, regulatory rewiring in specific models, reversible copy-number adaptation during targeted therapies, and replication-stress vulnerabilities in preclinical systems. In contrast, associations with reduced antigen presentation, altered interferon signaling, immune-cell exclusion, chemotherapy resistance, radiotherapy response, and immunotherapy failure remain context-dependent and not universally causal. When discussing the cGAS–STING pathway, intact nuclear ecDNA is differentiated from micronuclear DNA and damaged cytosolic fragments. Therapeutic strategies are classified based on direct preclinical evidence for ecDNA specificity, ecDNA-associated evidence, indirect biological reasoning, or a conceptual hypothesis; no strategy is presented as an established treatment directed at ecDNA. Detection methods are arranged from amplification screening to breakpoint-resolved inference to independent physical confirmation. Clinically useful driver biomarkers are separated from candidate ecDNA biomarkers that require prospective validation. The main conclusion is that ecDNA is an established driver of tumor evolution but has not yet been broadly validated as an immune-evasion mechanism, a predictive biomarker, or a routine therapeutic target.
Related
- Understanding diagnostic challenges and identifying priorities to tackle antimicrobial resistance in conflict zones
- Antigen-Presentation Competence in Gynecologic Cancers: Mechanisms, Evidence and Translational Priorities.
- Smallholder farmers' preferences for public expenditure priorities to support maize productivity: evidence from a best–worst scaling experiment in western Kenya
- Extracellular vesicle-mediated immune escape in osteosarcoma: mechanisms, evidence gaps and translational priorities
- Pyroptosis in systemic lupus erythematosus and lupus nephritis: evidence grading, cellular crosstalk, and translational priorities
BibTeX
@article{rehman2026from,
title = {{From ecDNA structure to tumor immune escape and therapeutic resistance: evidence, uncertainty, and clinical priorities}},
author = {Shafee Ur Rehman},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1980333},
url = {https://doi.org/10.3389/fonc.2026.1980333},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - From ecDNA structure to tumor immune escape and therapeutic resistance: evidence, uncertainty, and clinical priorities
AU - Shafee Ur Rehman
PY - 2026
DA - 2026/10/23
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1980333
UR - https://doi.org/10.3389/fonc.2026.1980333
AB - Extrachromosomal DNA (ecDNA) is a structurally distinct form of focal amplification that can increase oncogene dosage, reorganize enhancer–promoter interactions, and accelerate tumor evolution through unequal segregation. This review presents a single, evidence-based sequence: the structure of ecDNA confers an evolutionary capacity; selection then acts upon the genes and regulatory elements that are carried by ecDNA; the clones that have been selected may subsequently develop treatment-adaptive or immune-associated traits; and clinical application can only proceed once it has been demonstrated that ecDNA provides information that goes beyond what is seen in conventional amplification. The strongest evidence comes from unequal segregation, regulatory rewiring in specific models, reversible copy-number adaptation during targeted therapies, and replication-stress vulnerabilities in preclinical systems. In contrast, associations with reduced antigen presentation, altered interferon signaling, immune-cell exclusion, chemotherapy resistance, radiotherapy response, and immunotherapy failure remain context-dependent and not universally causal. When discussing the cGAS–STING pathway, intact nuclear ecDNA is differentiated from micronuclear DNA and damaged cytosolic fragments. Therapeutic strategies are classified based on direct preclinical evidence for ecDNA specificity, ecDNA-associated evidence, indirect biological reasoning, or a conceptual hypothesis; no strategy is presented as an established treatment directed at ecDNA. Detection methods are arranged from amplification screening to breakpoint-resolved inference to independent physical confirmation. Clinically useful driver biomarkers are separated from candidate ecDNA biomarkers that require prospective validation. The main conclusion is that ecDNA is an established driver of tumor evolution but has not yet been broadly validated as an immune-evasion mechanism, a predictive biomarker, or a routine therapeutic target.
SN - 2234-943X
ER -